10x Genomics (NASDAQ:TXG – Get Free Report) CEO Serge Saxonov sold 10,486 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $63.69, for a total value of $667,853.34. Following the sale, the chief executive officer owned 1,075,349 shares in the company, valued at approximately $68,488,977.81. The trade was a 0.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Serge Saxonov also recently made the following trade(s):
- On Monday, August 24th, Serge Saxonov sold 18,545 shares of 10x Genomics stock. The stock was sold at an average price of $63.02, for a total value of $1,168,705.90.
- On Monday, June 22nd, Serge Saxonov sold 30,000 shares of 10x Genomics stock. The stock was sold at an average price of $34.44, for a total value of $1,033,200.00.
10x Genomics Stock Performance
Shares of TXG stock traded down $3.31 during trading hours on Friday, hitting $61.54. 2,360,727 shares of the company were exchanged, compared to its average volume of 3,311,234. The firm has a market cap of $8.02 billion, a P/E ratio of -104.30 and a beta of 2.03. 10x Genomics has a fifty-two week low of $11.16 and a fifty-two week high of $66.94. The company has a 50 day simple moving average of $47.62 and a two-hundred day simple moving average of $31.62.
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the stock. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of 10x Genomics during the second quarter valued at approximately $2,377,000. California State Teachers Retirement System lifted its stake in 10x Genomics by 3,700.4% during the 2nd quarter. California State Teachers Retirement System now owns 4,679,895 shares of the company’s stock valued at $179,427,000 after acquiring an additional 4,556,753 shares in the last quarter. HB Wealth Management LLC bought a new position in 10x Genomics during the 2nd quarter valued at $285,000. Three Seasons Wealth LLC purchased a new position in 10x Genomics during the 2nd quarter worth $208,000. Finally, Concurrent Investment Advisors LLC purchased a new position in 10x Genomics during the 2nd quarter worth $213,000. Institutional investors own 84.68% of the company’s stock.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the stock. Piper Sandler lifted their price target on shares of 10x Genomics from $42.00 to $47.00 and gave the company a “neutral” rating in a research note on Monday, August 10th. Canaccord Genuity Group increased their price objective on shares of 10x Genomics from $50.00 to $60.00 and gave the stock a “buy” rating in a research report on Monday, August 10th. Morgan Stanley raised their target price on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Zacks Research lowered 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 18th. Finally, TD Cowen reaffirmed a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $38.31.
Get Our Latest Analysis on TXG
About 10x Genomics
10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.
Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.
Featured Articles
- Five stocks we like better than 10x Genomics
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
